TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Functional assessment of chronic illness therapy-Spiritual Well-being Scale Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Febrile episodes rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of participants with PTSD diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Global Composite Cognition Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Non-relapse mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Angular measurement-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angular measurement-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angular measurement-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linear measurement-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linear measurement-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linear measurement-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with Interference
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Device and Procedure Related Serious Adverse Events (SAE) 180 Days Post Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Complete Closure of the Ductus Arteriosus at the Six-month Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the curve from time zero to last quantifiable concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with overall objective response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in antral follicle count (AFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Initial Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in aortic transvalvular gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: longitudinal change in psychological responses
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in self-reported upper extremity function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in self-reported pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Number of Components of the ICU Recovery Program Received
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants with MRI-confirmed acute ischemic stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Duration of cooling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean changes in ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean changes in motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean changes in fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean changes in quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of chorioamnionitis/intrapartum fever in infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pain Pressure Threshold of Temporalis Muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pain Pressure Threshold of Masseter Muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pain Pressure Threshold of Trapezius Muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of Hp 1-1 phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving prophylactic aPTT-range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Soft tissue profile change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude and duration of external anal sphincter contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Mitral Regurgitation Classes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Average Pain Severity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose level (MTDL)
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events of radiation therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Kidney Disease Quality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Need for systemic analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Passage of Flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Biopsy confirmed high-grade cervical intraepithelial neoplasia (CIN) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Purdue Pegboard
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ETEC diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Subjects With Clinical Cardiac Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Musculoskeletal Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Glycemic control measured via HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: OX-LDL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stroke or TIA
Endpoint domain: Mortality/survival
Primary endpoint: True positive and negative percent agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients who are able to complete therapy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Rate of patients responder at M12 after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tooth Hypersensitivity to Air Stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Rankin scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cataracts on Ophthalmologist's Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmological outcomes
Primary endpoint: Increase of Lens Autofluorescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmological outcomes
Primary endpoint: Increase of Lens Density on Scheimpflug Photography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmological outcomes
Primary endpoint: Number of Subjects With Major Pathological Response (MPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic rate of whole exome sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of ERCP guided biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of different types of periampullary masses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Abstinence From Cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Maintaining Hemoglobin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-mumps Virus Antibody Concentration Equal to or Above the Cut-off-value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-rubella Virus Antibody Concentration Equal to or Above the Cut-off-value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative Rates of Participants With NCI-CTCAE Grade 2 or Higher Peripheral Sensory Neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Least-squares Means of FACT/GOG-Ntx-12 Score at Cycle 12
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Discontinuation Rate of Oxaliplatin Due to OIPN
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Biomarkers for cardiovascular risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Number of Night Sweats
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Hot Flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of Subjective Hot Flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transition time to complementary diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of autologous PBSC infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of gene transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Knee Society Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Merle D'Aubigne' scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Provider Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Provider Certainty and Confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Provider global impression of change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: number of acute otitis media
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: quality of life issues
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Child dietary diversity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food consumption score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Familiar Hypercholesterolaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in cytokine clearances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Non-Hematological toxicity > grade three
Endpoint domain: Adverse events/effects
Primary endpoint: Symptom impact
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: LVESVI change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vaccine specific antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total amount of morphine required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cardiorespiratory effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of EPZ-5676
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-HBs antibody concentrations
Endpoint domain: Physiological/clinical
Primary endpoint: Assisting Hand Assessment 5.0
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Detection rate of cancer related genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of newborns with weight inferior to the 10th percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: endotoxin-induced airway inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of Major Adverse Cardiac Events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Fever reduction to less than 101.0 degrees Fahrenheit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients completing the study treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Toxicity of the regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Force generated by operative extremity - walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Force generated by operative extremity - standing from seated position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Force generated by operative extremity - squatting to a seated position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Force generated by operative extremity - walking up stairs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants Who Reached and Maintained Target Hemoglobin Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Inter-rater reliability of Silverman-Andersen Retraction Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Failure Related Clinical Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in QTc-interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain in the shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate (ORR) in R/R NHL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate (ORR) in R/R ALL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Residual Disease (MRD) negativity rates in R/R ALL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects reaching an Eliciting Dose ≥ 1,000 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Microscopically Confirmed Episodes of Infusion Set Occlusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual encounter profile question 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to 5 Year Endpoint in Blood Pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline to 5 Year Endpoint in Pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline to 5 Year Endpoint in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in MMSE score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: fear of COVID-19
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Superficial capillary plexus foveal avascular zone area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of failure
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Mean Off Time (Hours Per Day) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Nasal Obstruction Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of Posterior Choana Obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Referred to Surgery (Adenoidectomy)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: changes in pharmacokinetics of oral immunosuppressive medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of weight loss achieved after bariatric surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in general quality of life score, SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Composite of all-cause mortality, stroke, life-threatening and major bleeding events, stage 2 or 3 acute kidney injury, or major vascular complications
Endpoint domain: Mortality/survival
Primary endpoint: Composite of all-cause mortality, disabling stroke, or moderate or greater paravalvular aortic regurgitation
Endpoint domain: Mortality/survival
Primary endpoint: AUC0-last: Area Under the Plasma Concentration-time Curve of Decitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-last: Area Under the Plasma Concentration-time Curve of Cedazuridine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With an Adverse Drug Reaction (ADR)
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Anxiety state (STAI-Y scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Anxiety state (AE scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Electromyography Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Postoperative Nausea and Vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Corticoid-sparing effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transition Dyspnea Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of weekly hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Measures of dyssynchrony parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Modified Total Sharp Score (mTSS) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in perinatal and neonatal mortality
Endpoint domain: Mortality/survival
Primary endpoint: Serum Interleukin-8 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Protein profile in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activity in response to noxious stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain Diagram and Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Neck Disability Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Abstinence of tobacco consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Postoperative events
Endpoint domain: Adverse events/effects
Primary endpoint: Full achievement of copy spelling tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Full achievement of free spelling tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: C peptide release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean Change in Protein C Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Disease stabilization at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-Minute Walk Test (6MWT) at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Adoption of Healthy Eating
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline in Adoption of Exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline in Adoption of Effective Stress Management
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Subjects With Evidence of Bacteria in Urine Sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: quadriceps muscle cross-sectional area (CSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in the incidence of pulmonary exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of intestinal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient family satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients positive for IgG or IgM against PUUV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes